

Andreas Baumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8633636/publications.pdf>

Version: 2024-02-01

24
papers

1,007
citations

567281

15
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

1254
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting. <i>MAbs</i> , 2021, 13, 1938796.	5.2	4
2	Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use. <i>International Journal of Toxicology</i> , 2021, 40, 270-284.	1.2	3
3	PEGylated biologics in haemophilia treatment: Current understanding of their long-term safety. <i>Haemophilia</i> , 2020, 26, e11-e13.	2.1	12
4	Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 11-20.	4.0	27
5	Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. <i>AAPS Journal</i> , 2017, 19, 1186-1195.	4.4	39
6	Leverage nonclinical development of bispecifics by translational science. <i>Drug Discovery Today: Technologies</i> , 2016, 21-22, 95-102.	4.0	4
7	Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 265-275.	2.7	14
8	PEGylated Biopharmaceuticals. <i>Toxicologic Pathology</i> , 2015, 43, 959-983.	1.8	136
9	Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?. <i>Drug Discovery Today</i> , 2014, 19, 1623-1631.	6.4	118
10	Pharmacokinetics and Excretion of 14C-Labeled Polyethylene Glycol (60 kDa) in Rats. <i>Blood</i> , 2014, 124, 1473-1473.	1.4	16
11	<sc>PEG</sc>ylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. <i>Haemophilia</i> , 2013, 19, 11-20.	2.1	96
12	Nonclinical development of biopharmaceuticals. <i>Drug Discovery Today</i> , 2009, 14, 1112-1122.	6.4	25
13	Preclinical development of therapeutic biologics. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 289-297.	5.0	7
14	Population pharmacokinetics?pharmacodynamics of alemtuzumab (Campath $\frac{1}{2}$) in patients with chronic lymphocytic leukaemia and its link to treatment response. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 278-291.	2.4	115
15	Early Development of Therapeutic Biologics - Pharmacokinetics. <i>Current Drug Metabolism</i> , 2006, 7, 15-21.	1.2	114
16	In Vitro Model of the Human Liver Parenchyma to Study Hepatotoxic Side Effects of Dy-EOB-DTPA. <i>Investigative Radiology</i> , 2000, 35, 373-379.	6.2	9
17	Use of precision cut human liver slices for studying the metabolism and genotoxic potential of xenobiotics by means of the 32 P-postlabelling technique: steps towards method validation using testosterone and 2-aminofluorene. <i>Biomarkers</i> , 1999, 4, 188-202.	1.9	1
18	DNA Adduct Formation of Selected Sex Steroids in Human Liver Slices In Vitro. <i>Toxicology in Vitro</i> , 1998, 12, 353-364.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. <i>Contraception</i> , 1996, 54, 235-242.	1.5	10
20	Use of Rat and Human Liver Slices for the Detection of Steroid Hormone-Induced DNA-Adducts <i>in vitro</i> by Means of the ³² P-Postlabeling Technique. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 214-223.	0.0	23
21	The Use of Tissue Slices for Pharmacotoxicology Studies. <i>ATLA Alternatives To Laboratory Animals</i> , 1996, 24, 893-919.	1.0	82
22	Identification of 3 β -hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts <i>in vitro</i> . <i>Carcinogenesis</i> , 1995, 16, 1835-1841.	2.8	25
23	Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. <i>Contraception</i> , 1993, 48, 303-322.	1.5	18
24	Determination of the β -adrenoceptor blocking drug B24/76 in serum by high-performance liquid chromatography with fluorimetric detection after pre-column dansylation. <i>Biomedical Applications</i> , 1989, 488, 482-486.	1.7	2